{"filing":{"accession_number":"0001171520-26-000225","cik":"0001035422","ticker":"CTTH","company_name":"CTT PHARMACEUTICAL HOLDINGS, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-11","primary_document":"eps12766_ctth.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1035422/000117152026000225/eps12766_ctth.htm"},"events":[{"id":27036,"run_id":24605,"accession_number":"0001171520-26-000225","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CTT Pharmaceutical received a continuation-in-part (CIP) patent approval from the U.S. Patent Office for its micelle delivery technology covering nicotine, vitamins, and caffeine applications (effective August 11, 2026). This is a material operational/strategic event—patent protection strengthens the company's competitive position and enables commercialization of multiple product forms (strips, gum, pouches, lozenges, tablets). While not a named event type, it is clearly operational and strategic in nature, making it an operational_other classification rather than a routine administrative disclosure.","company_name":"CTT PHARMACEUTICAL HOLDINGS, INC.","ticker":"CTTH","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28393,"accession_number":"0001171520-26-000225","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CTT Pharmaceutical received a continuation-in-part (CIP) patent approval from the U.S. Patent Office for its micelle delivery technology covering nicotine, vitamins, and caffeine applications (effective August 11, 2026). This is a material operational/strategic event—patent protection strengthens the company's competitive position and enables commercialization of multiple product forms (strips, gum, pouches, lozenges, tablets). While not a named event type, it is clearly operational and strategic in nature, making it an operational_other classification rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:32:40.465566+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28393,"accession_number":"0001171520-26-000225","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CTT Pharmaceutical received a continuation-in-part (CIP) patent approval from the U.S. Patent Office for its micelle delivery technology covering nicotine, vitamins, and caffeine applications (effective August 11, 2026). This is a material operational/strategic event—patent protection strengthens the company's competitive position and enables commercialization of multiple product forms (strips, gum, pouches, lozenges, tablets). While not a named event type, it is clearly operational and strategic in nature, making it an operational_other classification rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:32:40.465566+00:00","company_name":"CTT PHARMACEUTICAL HOLDINGS, INC.","ticker":"CTTH","filing_date":"2026-08-12"}]}